Condition: Polycythemia Vera · Essential Thrombocythemia · Prefibrotic/Early Primary Myelofibrosis · Sponsor: University Hospital, Brest
Philadelphia-negative myeloproliferative neoplasms (MPN) are frequent and chronic myeloid malignancies including Polycythemia Vera (PV), essential thrombocythemia (ET), Primary Myelofibrosis (PMF) and Prefibrotic myelofibrosis (PreMF). These MPNs are caused by the acquisition of mutations affecting activation/proliferation pathways in hematopoietic stem cells. The principal mutations are JAK2V617F, calreticulin (CALR exon 9) and MPL W515. ET or MFP/PreMF patients who do not carry one of these three mutations are declared as triple-negative (3NEG) cases even if they are real MPN cases. These diseases are at high risk of thrombo-embolic complications and with high morbidity/mortality. This risk varies from 4 to 30% depending on MPN subtype and mutational status. In terms of therapy, all patients with MPNs should also take daily low-dose aspirin (LDA) as first antithrombotic drug, which is particularly efficient to reduce arterial but not venous events. Despite the association of a cytoreductive drug and LDA, thromboses still occur in 5-8% patients/year. All these situations have been explored in biological or clinical assays. All of them could increase the bleeding risk. We should look at different ways to reduce the thrombotic incidence: Direct Oral Anticoagulants (DOAC)? In the general population, in medical or surgical contexts, DOACs have demonstrated their efficiency to prevent or cure most of the venous or arterial thrombotic events. At the present time, DOAC can be …
This description comes directly from the study's public registry record.
Jean-Christophe IANOTTO, Pr · +33298223421 · jean-christophe.ianotto@chu-brest.fr
Always discuss trial participation with your own doctor first.
| CHU d'Angers | Angers, France | Recruiting |
| CH d'Annecy | Annecy, France | Not Yet Recruiting |
| CH d'Argenteuil | Argenteuil, France | Not Yet Recruiting |
| CH d'Avignon | Avignon, France | Recruiting |
| CH de la Côte Basque Bayonne | Bayonne, France | Not Yet Recruiting |
| CH de Béziers | Béziers, France | Not Yet Recruiting |
| CHU Bordeaux | Bordeaux, France | Recruiting |
| CHU Brest | Brest, France | Recruiting |
| Hôpital privé Cesson-Sévigné | Cesson-Sévigné, France | Not Yet Recruiting |
| CHU de Clermont-Ferrand | Clermont-Ferrand, France | Not Yet Recruiting |
| Hôpital Henri Mondor (APHP) | Créteil, France | Recruiting |
| CHU Grenoble Alpes | Grenoble, France | Recruiting |
+ 30 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05198960